Identifying predictors of early trial termination: a meta-epidemiological study utilising elements of the research ethics committee evaluation

Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review process provides a window for both identifying trials at high risk of terminating prematurely and imposing preventive measures, such as design...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical epidemiology Vol. 184; p. 111832
Main Authors Jansen, Marieke S., Pet, Lodewijk A., Buijs, Jeroen T., Siegerink, Bob, Groenwold, Rolf H.H., Dekkers, Olaf M.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.08.2025
Elsevier Limited
Subjects
Online AccessGet full text
ISSN0895-4356
1878-5921
DOI10.1016/j.jclinepi.2025.111832

Cover

Abstract Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review process provides a window for both identifying trials at high risk of terminating prematurely and imposing preventive measures, such as design modifications. This study aimed to explore whether characteristics of ethics review, alongside trial characteristics, are related to subsequent early trial termination. This meta-epidemiological cohort study assessed 198 clinical trials approved by a Dutch REC between 2015 and 2018. Data from archived trial protocols, related study documents, and correspondence between the REC and investigators were analysed to identify predictors of early termination during ethics review. Of the 198 trials, 69 (34.8%) terminated early, most often due to recruitment failure (n = 31, 35.2%). Several characteristics were associated with early termination, such as multicentre design (vs single centre, risk ratio [RR]: 1.89, 95% CI: 1.24–3.14), number of comments raised during ethics review (per comment, RR: 1.02, 95% CI: 1.00–1.05), and specific comments regarding privacy and confidentiality (RR: 1.21, 95% CI: 1.05–1.41) and participant information sheets (RR: 1.05, 95% CI: 1.02–1.08). Investigator sponsorship, longer review durations, and comments raised regarding privacy and confidentiality and subject selection were associated with an increased likelihood of recruitment failure, specifically. This exploratory study showed that various characteristics of ethics review have the potential to predict early trial termination. Further studies are needed to validate and expand upon these findings. Clinical trials sometimes end earlier than planned, often due to difficulties recruiting enough participants. When trials stop too soon, their results become less reliable. Research ethics committees (RECs) review trial plans before they begin to make sure they meet legal and ethical standards. RECs may also be able to help prevent early termination by identifying trials at high risk and recommending improvements. This study looked at 198 clinical trials approved by a Dutch REC to see if the characteristics of the ethics review process could predict which trials might stop early. The study found that about one-third of the trials ended early, most often due to recruitment problems. Trials were more likely to stop early if they involved multiple centres, received more comments from the REC, or received comments specifically about issues related to privacy, confidentiality, or the information given to participants. Recruitment problems were more common in trials that had longer review times, received comments about who was eligible to take part or issues related to privacy and confidentiality, or were run by researchers without commercial sponsorship. Overall, the findings suggest that by examining the ethics review process more closely, RECs might be able to identify and support trials at higher risk of stopping early. More research is needed to confirm these results and explore how RECs might help improve trial success. •Around one-third of clinical trials stop early, often due to recruitment failure.•Research ethics committees may help reduce the risk of early termination.•This study showed that aspects of ethics review can help predict early termination.•Review time, number and type of comments were linked to early trial termination.•Multicenter design was linked to termination and sponsorship to recruitment failure.
AbstractList Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review process provides a window for both identifying trials at high risk of terminating prematurely and imposing preventive measures, such as design modifications. This study aimed to explore whether characteristics of ethics review, alongside trial characteristics, are related to subsequent early trial termination. This meta-epidemiological cohort study assessed 198 clinical trials approved by a Dutch REC between 2015 and 2018. Data from archived trial protocols, related study documents, and correspondence between the REC and investigators were analysed to identify predictors of early termination during ethics review. Of the 198 trials, 69 (34.8%) terminated early, most often due to recruitment failure (n = 31, 35.2%). Several characteristics were associated with early termination, such as multicentre design (vs single centre, risk ratio [RR]: 1.89, 95% CI: 1.24-3.14), number of comments raised during ethics review (per comment, RR: 1.02, 95% CI: 1.00-1.05), and specific comments regarding privacy and confidentiality (RR: 1.21, 95% CI: 1.05-1.41) and participant information sheets (RR: 1.05, 95% CI: 1.02-1.08). Investigator sponsorship, longer review durations, and comments raised regarding privacy and confidentiality and subject selection were associated with an increased likelihood of recruitment failure, specifically. This exploratory study showed that various characteristics of ethics review have the potential to predict early trial termination. Further studies are needed to validate and expand upon these findings. Clinical trials sometimes end earlier than planned, often due to difficulties recruiting enough participants. When trials stop too soon, their results become less reliable. Research ethics committees (RECs) review trial plans before they begin to make sure they meet legal and ethical standards. RECs may also be able to help prevent early termination by identifying trials at high risk and recommending improvements. This study looked at 198 clinical trials approved by a Dutch REC to see if the characteristics of the ethics review process could predict which trials might stop early. The study found that about one-third of the trials ended early, most often due to recruitment problems. Trials were more likely to stop early if they involved multiple centres, received more comments from the REC, or received comments specifically about issues related to privacy, confidentiality, or the information given to participants. Recruitment problems were more common in trials that had longer review times, received comments about who was eligible to take part or issues related to privacy and confidentiality, or were run by researchers without commercial sponsorship. Overall, the findings suggest that by examining the ethics review process more closely, RECs might be able to identify and support trials at higher risk of stopping early. More research is needed to confirm these results and explore how RECs might help improve trial success.
Objectives Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review process provides a window for both identifying trials at high risk of terminating prematurely and imposing preventive measures, such as design modifications. This study aimed to explore whether characteristics of ethics review, alongside trial characteristics, are related to subsequent early trial termination. Study Design and Setting This meta-epidemiological cohort study assessed 198 clinical trials approved by a Dutch REC between 2015 and 2018. Data from archived trial protocols, related study documents, and correspondence between the REC and investigators were analysed to identify predictors of early termination during ethics review. Results Of the 198 trials, 69 (34.8%) terminated early, most often due to recruitment failure ( n = 31, 35.2%). Several characteristics were associated with early termination, such as multicentre design (vs single centre, risk ratio [RR]: 1.89, 95% CI: 1.24–3.14), number of comments raised during ethics review (per comment, RR: 1.02, 95% CI: 1.00–1.05), and specific comments regarding privacy and confidentiality (RR: 1.21, 95% CI: 1.05–1.41) and participant information sheets (RR: 1.05, 95% CI: 1.02–1.08). Investigator sponsorship, longer review durations, and comments raised regarding privacy and confidentiality and subject selection were associated with an increased likelihood of recruitment failure, specifically. Conclusion This exploratory study showed that various characteristics of ethics review have the potential to predict early trial termination. Further studies are needed to validate and expand upon these findings. Plain Language Summary Clinical trials sometimes end earlier than planned, often due to difficulties recruiting enough participants. When trials stop too soon, their results become less reliable. Research ethics committees (RECs) review trial plans before they begin to make sure they meet legal and ethical standards. RECs may also be able to help prevent early termination by identifying trials at high risk and recommending improvements. This study looked at 198 clinical trials approved by a Dutch REC to see if the characteristics of the ethics review process could predict which trials might stop early. The study found that about one-third of the trials ended early, most often due to recruitment problems. Trials were more likely to stop early if they involved multiple centres, received more comments from the REC, or received comments specifically about issues related to privacy, confidentiality, or the information given to participants. Recruitment problems were more common in trials that had longer review times, received comments about who was eligible to take part or issues related to privacy and confidentiality, or were run by researchers without commercial sponsorship. Overall, the findings suggest that by examining the ethics review process more closely, RECs might be able to identify and support trials at higher risk of stopping early. More research is needed to confirm these results and explore how RECs might help improve trial success.
Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review process provides a window for both identifying trials at high risk of terminating prematurely and imposing preventive measures, such as design modifications. This study aimed to explore whether characteristics of ethics review, alongside trial characteristics, are related to subsequent early trial termination. This meta-epidemiological cohort study assessed 198 clinical trials approved by a Dutch REC between 2015 and 2018. Data from archived trial protocols, related study documents, and correspondence between the REC and investigators were analysed to identify predictors of early termination during ethics review. Of the 198 trials, 69 (34.8%) terminated early, most often due to recruitment failure (n = 31, 35.2%). Several characteristics were associated with early termination, such as multicentre design (vs single centre, risk ratio [RR]: 1.89, 95% CI: 1.24–3.14), number of comments raised during ethics review (per comment, RR: 1.02, 95% CI: 1.00–1.05), and specific comments regarding privacy and confidentiality (RR: 1.21, 95% CI: 1.05–1.41) and participant information sheets (RR: 1.05, 95% CI: 1.02–1.08). Investigator sponsorship, longer review durations, and comments raised regarding privacy and confidentiality and subject selection were associated with an increased likelihood of recruitment failure, specifically. This exploratory study showed that various characteristics of ethics review have the potential to predict early trial termination. Further studies are needed to validate and expand upon these findings. Clinical trials sometimes end earlier than planned, often due to difficulties recruiting enough participants. When trials stop too soon, their results become less reliable. Research ethics committees (RECs) review trial plans before they begin to make sure they meet legal and ethical standards. RECs may also be able to help prevent early termination by identifying trials at high risk and recommending improvements. This study looked at 198 clinical trials approved by a Dutch REC to see if the characteristics of the ethics review process could predict which trials might stop early. The study found that about one-third of the trials ended early, most often due to recruitment problems. Trials were more likely to stop early if they involved multiple centres, received more comments from the REC, or received comments specifically about issues related to privacy, confidentiality, or the information given to participants. Recruitment problems were more common in trials that had longer review times, received comments about who was eligible to take part or issues related to privacy and confidentiality, or were run by researchers without commercial sponsorship. Overall, the findings suggest that by examining the ethics review process more closely, RECs might be able to identify and support trials at higher risk of stopping early. More research is needed to confirm these results and explore how RECs might help improve trial success. •Around one-third of clinical trials stop early, often due to recruitment failure.•Research ethics committees may help reduce the risk of early termination.•This study showed that aspects of ethics review can help predict early termination.•Review time, number and type of comments were linked to early trial termination.•Multicenter design was linked to termination and sponsorship to recruitment failure.
AbstractObjectivesEarly trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review process provides a window for both identifying trials at high risk of terminating prematurely and imposing preventive measures, such as design modifications. This study aimed to explore whether characteristics of ethics review, alongside trial characteristics, are related to subsequent early trial termination. Study Design and SettingThis meta-epidemiological cohort study assessed 198 clinical trials approved by a Dutch REC between 2015 and 2018. Data from archived trial protocols, related study documents, and correspondence between the REC and investigators were analysed to identify predictors of early termination during ethics review. ResultsOf the 198 trials, 69 (34.8%) terminated early, most often due to recruitment failure ( n = 31, 35.2%). Several characteristics were associated with early termination, such as multicentre design (vs single centre, risk ratio [RR]: 1.89, 95% CI: 1.24–3.14), number of comments raised during ethics review (per comment, RR: 1.02, 95% CI: 1.00–1.05), and specific comments regarding privacy and confidentiality (RR: 1.21, 95% CI: 1.05–1.41) and participant information sheets (RR: 1.05, 95% CI: 1.02–1.08). Investigator sponsorship, longer review durations, and comments raised regarding privacy and confidentiality and subject selection were associated with an increased likelihood of recruitment failure, specifically. ConclusionThis exploratory study showed that various characteristics of ethics review have the potential to predict early trial termination. Further studies are needed to validate and expand upon these findings. Plain Language SummaryClinical trials sometimes end earlier than planned, often due to difficulties recruiting enough participants. When trials stop too soon, their results become less reliable. Research ethics committees (RECs) review trial plans before they begin to make sure they meet legal and ethical standards. RECs may also be able to help prevent early termination by identifying trials at high risk and recommending improvements. This study looked at 198 clinical trials approved by a Dutch REC to see if the characteristics of the ethics review process could predict which trials might stop early. The study found that about one-third of the trials ended early, most often due to recruitment problems. Trials were more likely to stop early if they involved multiple centres, received more comments from the REC, or received comments specifically about issues related to privacy, confidentiality, or the information given to participants. Recruitment problems were more common in trials that had longer review times, received comments about who was eligible to take part or issues related to privacy and confidentiality, or were run by researchers without commercial sponsorship. Overall, the findings suggest that by examining the ethics review process more closely, RECs might be able to identify and support trials at higher risk of stopping early. More research is needed to confirm these results and explore how RECs might help improve trial success.
ArticleNumber 111832
Author Buijs, Jeroen T.
Groenwold, Rolf H.H.
Pet, Lodewijk A.
Siegerink, Bob
Dekkers, Olaf M.
Jansen, Marieke S.
Author_xml – sequence: 1
  givenname: Marieke S.
  orcidid: 0000-0001-5669-2593
  surname: Jansen
  fullname: Jansen, Marieke S.
  email: m.s.jansen@lumc.nl
  organization: Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands
– sequence: 2
  givenname: Lodewijk A.
  orcidid: 0000-0002-2792-4460
  surname: Pet
  fullname: Pet, Lodewijk A.
  organization: Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands
– sequence: 3
  givenname: Jeroen T.
  surname: Buijs
  fullname: Buijs, Jeroen T.
  organization: Medical Research Ethics Committee Leiden The Hague Delft, Leiden, The Netherlands
– sequence: 4
  givenname: Bob
  orcidid: 0000-0002-8454-9142
  surname: Siegerink
  fullname: Siegerink, Bob
  organization: Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands
– sequence: 5
  givenname: Rolf H.H.
  orcidid: 0000-0001-9238-6999
  surname: Groenwold
  fullname: Groenwold, Rolf H.H.
  organization: Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands
– sequence: 6
  givenname: Olaf M.
  surname: Dekkers
  fullname: Dekkers, Olaf M.
  organization: Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40368224$$D View this record in MEDLINE/PubMed
BookMark eNqNkstO3TAQhq0KVA60r4AsdZ1TX3PpomqFekFC6gJYW4494ThN4lPbQcpL8Mx1OMCii7Yrb775xjP_nKKjyU-A0DklW0po-b7f9mZwE-zdlhEmt5TSmrNXaEPrqi5kw-gR2pC6kYXgsjxBpzH2hNCKVPI1OhGElzVjYoMeLi1MyXWLm-7wPoB1JvkQse8w6DAsOAWnB5wgjG7SyfnpA9Z4hKSL3NvC6Pzg75zJTEyzXfCc3ODiaoMBxux-dKUd4AAxK80OQ9o5E7Hx4-hSAsBwr4f5Uf4GHXd6iPD26T1Dt1-_3Fx8L65-fLu8-HxVGFGRVJRSiKpqmeTCNsxQwruG1h20wtrGtrwBpgkHTUlbMdESqm1Laq07Q42BsuJn6N3Buw_-1wwxqd7PYcotFWeCMklpxTN1_kTN7QhW7YMbdVjU8_oyUB4AE3yMAboXhBK15qR69ZyTWnNSh5xy4adDIeQh7x0EFY2DyeT9BzBJWe_-rfj4h2Kl1iR-wgLxZR6qIlNEXa_HsN4Ck_kOStn8XfA_P_gNNGXL2A
Cites_doi 10.1001/jama.2014.1361
10.1177/1740774514558307
10.1136/medethics-2011-100020
10.1056/EVIDoa2300003
10.1186/s13063-021-05818-0
10.1371/journal.pmed.1003980
10.1136/jme.2002.002105
10.1186/s12874-022-01617-6
10.1590/S1807-59322009000900002
10.1136/ebmed-2017-110713
10.1097/EDE.0b013e31818131e7
10.1186/s13063-019-3957-4
10.1186/1472-6939-15-83
10.1136/jme.25.3.274
ContentType Journal Article
Copyright 2025 The Author(s)
The Author(s)
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2025 The Author(s)
– notice: The Author(s)
– notice: Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7T2
7T7
7TK
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
NAPCQ
P64
DOI 10.1016/j.jclinepi.2025.111832
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Health and Safety Science Abstracts (Full archive)
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Toxicology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Technology Research Database
Toxicology Abstracts
ProQuest Health & Medical Complete (Alumni)
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Nursing & Allied Health Premium
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Health & Safety Science Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Calcium & Calcified Tissue Abstracts
DatabaseTitleList MEDLINE
Virology and AIDS Abstracts



Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1878-5921
EndPage 111832
ExternalDocumentID 40368224
10_1016_j_jclinepi_2025_111832
S0895435625001659
1_s2_0_S0895435625001659
Genre Journal Article
GeographicLocations Netherlands
GeographicLocations_xml – name: Netherlands
GroupedDBID ---
--K
--M
-~X
.1-
.55
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29K
4.4
457
4CK
4G.
53G
5GY
5RE
5VS
7-5
71M
7RV
7X7
88E
8AO
8C1
8FI
8FJ
8G5
8P~
9JM
9JO
AABNK
AAEDT
AAEDW
AAFJI
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYJJ
AAYWO
ABBQC
ABFNM
ABIVO
ABJNI
ABLJU
ABMAC
ABMMH
ABMZM
ABOCM
ABUWG
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACIUM
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEUYN
AEVXI
AFFNX
AFJKZ
AFKRA
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
AOMHK
APXCP
AQUVI
ASPBG
AVARZ
AVWKF
AXJTR
AZFZN
AZQEC
BENPR
BKEYQ
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
CCPQU
CS3
D-I
DU5
DWQXO
EBS
EFJIC
EFKBS
EFLBG
EJD
EMOBN
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-2
G-Q
GBLVA
GNUQQ
GUQSH
HEH
HMCUK
HMK
HMO
HVGLF
HZ~
IHE
J1W
KOM
L7B
M0T
M1P
M29
M2O
M3W
M41
MO0
N9A
NAPCQ
O-L
O9-
OAUVE
OD~
OHT
OO0
OZT
P-8
P-9
P2P
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PRBVW
PROAC
PSQYO
PUEGO
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSB
SSH
SSO
SSZ
SV3
T5K
UAP
UKHRP
WOW
WUQ
X7M
XPP
YHZ
Z5R
ZGI
~G-
AFCTW
AGRNS
ALIPV
RIG
6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7T2
7T7
7TK
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
ID FETCH-LOGICAL-c470t-654477b2534d92c103f918feb4dd9db39e2a03ea10b724b01adb08aafc1cce673
IEDL.DBID AIKHN
ISSN 0895-4356
IngestDate Thu Aug 21 03:50:36 EDT 2025
Tue Sep 09 02:32:19 EDT 2025
Wed Aug 27 16:39:41 EDT 2025
Sat Sep 06 17:16:48 EDT 2025
Fri Jun 27 03:51:14 EDT 2025
Mon Sep 08 07:22:08 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Clinical trials
Early termination
Research ethics committee
Institutional review board
Ethics approval
Premature discontinuation
Language English
License This is an open access article under the CC BY license.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c470t-654477b2534d92c103f918feb4dd9db39e2a03ea10b724b01adb08aafc1cce673
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ORCID 0000-0002-8454-9142
0000-0001-5669-2593
0000-0002-2792-4460
0000-0001-9238-6999
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0895435625001659
PMID 40368224
PQID 3241251173
PQPubID 105585
PageCount 1
ParticipantIDs proquest_journals_3241251173
pubmed_primary_40368224
crossref_primary_10_1016_j_jclinepi_2025_111832
elsevier_sciencedirect_doi_10_1016_j_jclinepi_2025_111832
elsevier_clinicalkeyesjournals_1_s2_0_S0895435625001659
elsevier_clinicalkey_doi_10_1016_j_jclinepi_2025_111832
PublicationCentury 2000
PublicationDate 2025-08-01
PublicationDateYYYYMMDD 2025-08-01
PublicationDate_xml – month: 08
  year: 2025
  text: 2025-08-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Elmsford
PublicationTitle Journal of clinical epidemiology
PublicationTitleAlternate J Clin Epidemiol
PublicationYear 2025
Publisher Elsevier Inc
Elsevier Limited
Publisher_xml – name: Elsevier Inc
– name: Elsevier Limited
References Kent (bib12) 1999; 25
Ioannidis (bib3) 2008; 19
Murad, Wang (bib9) 2017; 22
van Lent, Rongen, Out (bib11) 2014; 15
Kelleher, Stanton, Vale, Smith (bib15) 2013; 106
Bueno, Brevidelli, Cocarelli, Santos, Ferraz, Mion (bib14) 2009; 64
bib10
van Zwet, Gelman, Greenland, Imbens, Schwab, Goodman (bib4) 2024; 3
Speich, Gryaznov, Busse, Gloy, Lohner, Klatte (bib2) 2022; 19
Gloy, Speich, Griessbach (bib16) 2022; 22
Briel, Speich, von Elm, Gloy (bib6) 2019; 20
Damen, van Agt, de Boo, Huysmans (bib8) 2012; 38
Kasenda, von Elm, You, Blümle, Tomonaga, Saccilotto (bib1) 2014; 311
Carlisle, Kimmelman, Ramsay, MacKinnon (bib7) 2015; 12
Briel, Elger, McLennan, Schandelmaier, von Elm, Satalkar (bib5) 2021; 22
Sansone, McDonald, Hanley, Sellbom, Gaither (bib13) 2004; 30
Briel (10.1016/j.jclinepi.2025.111832_bib6) 2019; 20
Gloy (10.1016/j.jclinepi.2025.111832_bib16) 2022; 22
Bueno (10.1016/j.jclinepi.2025.111832_bib14) 2009; 64
Kent (10.1016/j.jclinepi.2025.111832_bib12) 1999; 25
van Lent (10.1016/j.jclinepi.2025.111832_bib11) 2014; 15
Damen (10.1016/j.jclinepi.2025.111832_bib8) 2012; 38
Kelleher (10.1016/j.jclinepi.2025.111832_bib15) 2013; 106
Sansone (10.1016/j.jclinepi.2025.111832_bib13) 2004; 30
Ioannidis (10.1016/j.jclinepi.2025.111832_bib3) 2008; 19
Kasenda (10.1016/j.jclinepi.2025.111832_bib1) 2014; 311
Speich (10.1016/j.jclinepi.2025.111832_bib2) 2022; 19
Briel (10.1016/j.jclinepi.2025.111832_bib5) 2021; 22
van Zwet (10.1016/j.jclinepi.2025.111832_bib4) 2024; 3
Carlisle (10.1016/j.jclinepi.2025.111832_bib7) 2015; 12
Murad (10.1016/j.jclinepi.2025.111832_bib9) 2017; 22
References_xml – volume: 22
  start-page: 844
  year: 2021
  ident: bib5
  article-title: Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada
  publication-title: Trials
– ident: bib10
  article-title: Your research: is it subject to the WMO or not?
– volume: 15
  start-page: 83
  year: 2014
  ident: bib11
  article-title: Shortcomings of protocols of drug trials in relation to sponsorship as identified by Research Ethics Committees: analysis of comments raised during ethical review
  publication-title: BMC Med Ethics
– volume: 64
  start-page: 831
  year: 2009
  end-page: 836
  ident: bib14
  article-title: Reasons for resubmission of research projects to the research ethics committee of a university hospital in Sao Paulo, Brazil
  publication-title: Clinics (Sao Paulo)
– volume: 12
  start-page: 77
  year: 2015
  end-page: 83
  ident: bib7
  article-title: Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials
  publication-title: Clin Trials
– volume: 19
  start-page: e1003980
  year: 2022
  ident: bib2
  article-title: Nonregistration, discontinuation, and nonpublication of randomized trials: a repeated metaresearch analysis
  publication-title: PLoS Med
– volume: 22
  start-page: 139
  year: 2017
  end-page: 142
  ident: bib9
  article-title: Guidelines for reporting meta-epidemiological methodology research
  publication-title: Evid Based Med
– volume: 22
  start-page: 142
  year: 2022
  ident: bib16
  article-title: Scoping review and characteristics of publicly available checklists for assessing clinical trial feasibility
  publication-title: BMC Med Res Methodol
– volume: 311
  start-page: 1045
  year: 2014
  end-page: 1051
  ident: bib1
  article-title: Prevalence, characteristics, and publication of discontinued randomized trials
  publication-title: JAMA
– volume: 20
  start-page: 800
  year: 2019
  ident: bib6
  article-title: Comparison of randomized controlled trials discontinued or revised for poor recruitment and completed trials with the same research question: a matched qualitative study
  publication-title: Trials
– volume: 38
  start-page: 413
  year: 2012
  end-page: 416
  ident: bib8
  article-title: Terminating clinical trials without sufficient subjects
  publication-title: J Med Ethics
– volume: 106
  start-page: 184
  year: 2013
  end-page: 185
  ident: bib15
  article-title: Recurring themes arising during medical research ethics committee review
  publication-title: Ir Med J
– volume: 19
  start-page: 640
  year: 2008
  end-page: 648
  ident: bib3
  article-title: Why most discovered true associations are inflated
  publication-title: Epidemiology
– volume: 25
  start-page: 274
  year: 1999
  end-page: 277
  ident: bib12
  article-title: Responses by four local research ethics committees to submitted proposals
  publication-title: J Med Ethics
– volume: 30
  start-page: 308
  year: 2004
  end-page: 310
  ident: bib13
  article-title: The stipulations of one institutional review board: a five year review
  publication-title: J Med Ethics
– volume: 3
  year: 2024
  ident: bib4
  article-title: A new look at P values for randomized clinical trials
  publication-title: NEJM Evid
– volume: 311
  start-page: 1045
  issue: 10
  year: 2014
  ident: 10.1016/j.jclinepi.2025.111832_bib1
  article-title: Prevalence, characteristics, and publication of discontinued randomized trials
  publication-title: JAMA
  doi: 10.1001/jama.2014.1361
– volume: 12
  start-page: 77
  issue: 1
  year: 2015
  ident: 10.1016/j.jclinepi.2025.111832_bib7
  article-title: Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials
  publication-title: Clin Trials
  doi: 10.1177/1740774514558307
– volume: 38
  start-page: 413
  issue: 7
  year: 2012
  ident: 10.1016/j.jclinepi.2025.111832_bib8
  article-title: Terminating clinical trials without sufficient subjects
  publication-title: J Med Ethics
  doi: 10.1136/medethics-2011-100020
– volume: 3
  issue: 1
  year: 2024
  ident: 10.1016/j.jclinepi.2025.111832_bib4
  article-title: A new look at P values for randomized clinical trials
  publication-title: NEJM Evid
  doi: 10.1056/EVIDoa2300003
– volume: 22
  start-page: 844
  issue: 1
  year: 2021
  ident: 10.1016/j.jclinepi.2025.111832_bib5
  article-title: Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada
  publication-title: Trials
  doi: 10.1186/s13063-021-05818-0
– volume: 19
  start-page: e1003980
  issue: 4
  year: 2022
  ident: 10.1016/j.jclinepi.2025.111832_bib2
  article-title: Nonregistration, discontinuation, and nonpublication of randomized trials: a repeated metaresearch analysis
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1003980
– volume: 30
  start-page: 308
  issue: 3
  year: 2004
  ident: 10.1016/j.jclinepi.2025.111832_bib13
  article-title: The stipulations of one institutional review board: a five year review
  publication-title: J Med Ethics
  doi: 10.1136/jme.2002.002105
– volume: 22
  start-page: 142
  issue: 1
  year: 2022
  ident: 10.1016/j.jclinepi.2025.111832_bib16
  article-title: Scoping review and characteristics of publicly available checklists for assessing clinical trial feasibility
  publication-title: BMC Med Res Methodol
  doi: 10.1186/s12874-022-01617-6
– volume: 64
  start-page: 831
  issue: 9
  year: 2009
  ident: 10.1016/j.jclinepi.2025.111832_bib14
  article-title: Reasons for resubmission of research projects to the research ethics committee of a university hospital in Sao Paulo, Brazil
  publication-title: Clinics (Sao Paulo)
  doi: 10.1590/S1807-59322009000900002
– volume: 22
  start-page: 139
  issue: 4
  year: 2017
  ident: 10.1016/j.jclinepi.2025.111832_bib9
  article-title: Guidelines for reporting meta-epidemiological methodology research
  publication-title: Evid Based Med
  doi: 10.1136/ebmed-2017-110713
– volume: 19
  start-page: 640
  issue: 5
  year: 2008
  ident: 10.1016/j.jclinepi.2025.111832_bib3
  article-title: Why most discovered true associations are inflated
  publication-title: Epidemiology
  doi: 10.1097/EDE.0b013e31818131e7
– volume: 106
  start-page: 184
  issue: 6
  year: 2013
  ident: 10.1016/j.jclinepi.2025.111832_bib15
  article-title: Recurring themes arising during medical research ethics committee review
  publication-title: Ir Med J
– volume: 20
  start-page: 800
  issue: 1
  year: 2019
  ident: 10.1016/j.jclinepi.2025.111832_bib6
  article-title: Comparison of randomized controlled trials discontinued or revised for poor recruitment and completed trials with the same research question: a matched qualitative study
  publication-title: Trials
  doi: 10.1186/s13063-019-3957-4
– volume: 15
  start-page: 83
  year: 2014
  ident: 10.1016/j.jclinepi.2025.111832_bib11
  article-title: Shortcomings of protocols of drug trials in relation to sponsorship as identified by Research Ethics Committees: analysis of comments raised during ethical review
  publication-title: BMC Med Ethics
  doi: 10.1186/1472-6939-15-83
– volume: 25
  start-page: 274
  issue: 3
  year: 1999
  ident: 10.1016/j.jclinepi.2025.111832_bib12
  article-title: Responses by four local research ethics committees to submitted proposals
  publication-title: J Med Ethics
  doi: 10.1136/jme.25.3.274
SSID ssj0017075
Score 2.4764073
Snippet Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review...
AbstractObjectivesEarly trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early...
Objectives Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination....
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 111832
SubjectTerms Clinical trials
Clinical Trials as Topic - ethics
Clinical Trials as Topic - statistics & numerical data
Correspondence
Design
Design modifications
Early termination
Early Termination of Clinical Trials - ethics
Early Termination of Clinical Trials - statistics & numerical data
Epidemiologic Studies
Epidemiology
Ethical standards
Ethics approval
Ethics Committees, Research - standards
Ethics Committees, Research - statistics & numerical data
Humans
Institutional review board
Internal Medicine
Medical research
Netherlands
Patient Selection
Premature discontinuation
Privacy
Recruitment
Reimbursement
Research ethics
Research ethics committee
Risk
Variables
Title Identifying predictors of early trial termination: a meta-epidemiological study utilising elements of the research ethics committee evaluation
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0895435625001659
https://www.clinicalkey.es/playcontent/1-s2.0-S0895435625001659
https://dx.doi.org/10.1016/j.jclinepi.2025.111832
https://www.ncbi.nlm.nih.gov/pubmed/40368224
https://www.proquest.com/docview/3241251173
Volume 184
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB3BIlW9VPR7C0U-9Go2dpw47g0h0LYVXFokbpadTNSsyrJi02t_Ar8ZT-wsVBVS1R5jxXHiGc88x_NmAD5g7gIMR81dqz1XWDpemcrzqsHWBXcvvCTu8Nl5Ob9Qny-Lyy04HrkwFFaZbH-06YO1Ti2zNJuzVdfNvmaVKYKzDwCecEthtmFH5qYsJrBz9OnL_HxzmKBjvl26n1OHB0ThxeGCGIi46sJWURZkQKpcPuajHsOggy863YVnCUSyo_iez2ELly_gyVk6Jn8Jt5F-O1CY2OqG2qmoDrtuGVJCYzbU6mApEIZE85E5doW943hfMZbEx4b0syxo54-O_iowjOHmw7MCdmQpWdB3hkPgPAvzeNX1PSK7zyP-Ci5OT74dz3kqvMBrpbOel4VSWntZ5KoxshZZ3hpRtehV05jG5waly3J0IvNaKp8J1_iscq6tRV1jqfPXMFleL_EtsGA-S2_QlZUzytCZZenDnjIoiMZCNvUUZuNU21XMr2HHwLOFHYVjSTg2CmcKepSIHdmjwd7Z4AL-rSeu07JdW2HX0mb2D9Wagtn0_E07_2rU_VFt7GagAGMJWQqdT-FNVKXN56sAKii2991_DLoHT-kqRiruw6S_-YnvA3rq_QFsH_4SB2mN3AFCGRzs
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VIgEXVN5bCvjA1d34kTjmhiqqBbq90Eq9WXYyEVm121U3XPkJ_OZ64mQLqiohuCZ2nHjGM5_jb2YA3qPyEYaj4b4xgWssPC9tGXhZY-OjuxdBUuzw_LiYneovZ_nZFhyMsTBEqxxsf7LpvbUerkyH2Zyu2nb6LSttHp19BPCEW3J7D-7rXBni9e3_3PA8hEnZdqk1p-a_hQkv9hcUf4irNm4UZU7mo1TyLg91FwLtPdHhDjweICT7mN7yCWzh8ik8mA-H5M_gVwq-7QOY2OqKrlNJHXbZMKR0xqyv1MEGGgwJ5gPz7AI7z_GmXiwJj_XJZ1nUzfOW_ikwTGTz_lkRObIhVdB3hj1tnsVZvGi7DpHdZBF_DqeHn04OZnwou8ArbbKOF7nWxgSZK11bWYlMNVaUDQZd17YOyqL0mUIvsmCkDpnwdchK75tKVBUWRr2A7eXlEl8Bi8azCBZ9UXqrLZ1YFiHuKKN6GMxlXU1gOk61W6XsGm6knS3cKBxHwnFJOBMwo0TcGDsarZ2LDuDfeuJ6WLRrJ9xauszdUqwJ2E3PP3Tzr0bdG9XGbQaKIJZwpTBqAi-TKm0-X0dIQcze3f8Y9B08nJ3Mj9zR5-Ovr-ER3UmcxT3Y7q5-4JuIo7rwtl8n17UIHbc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identifying+predictors+of+early+trial+termination%3A+a+meta-epidemiological+study+utilising+elements+of+the+research+ethics+committee+evaluation&rft.jtitle=Journal+of+clinical+epidemiology&rft.au=Jansen%2C+Marieke+S.&rft.au=Pet%2C+Lodewijk+A.&rft.au=Buijs%2C+Jeroen+T.&rft.au=Siegerink%2C+Bob&rft.date=2025-08-01&rft.pub=Elsevier+Inc&rft.issn=0895-4356&rft.volume=184&rft_id=info:doi/10.1016%2Fj.jclinepi.2025.111832&rft.externalDocID=S0895435625001659
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F08954356%2Fcov200h.gif